Compare · CDXC vs SISI
CDXC vs SISI
Side-by-side comparison of ChromaDex Corporation (CDXC) and Shineco Inc. (SISI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDXC and SISI operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CDXC has more recent analyst coverage (5 ratings vs 0 for SISI).
- Company
- ChromaDex Corporation
- Shineco Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 0
- 0
- Recent ratings
- 5
- 0
ChromaDex Corporation
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Shineco Inc.
Shineco, Inc., together with its subsidiaries, produces, distributes, and sells health and well-being focused plant-based products in China. It processes and distributes traditional Chinese herbal medicine products, as well as other pharmaceutical products directly to individual customers. The company also plants, processes, and distributes green and organic vegetables and fruits; and grows, cultivates, and sells yew trees that are used for the production of anti-cancer medication, as well as ornamental bonsai trees for purifying indoor air quality. In addition, it offers logistics services for agricultural products. Further, the company develops, manufactures, and distributes specialized fabrics, textiles, health supplements, and other byproducts derived from an indigenous Chinese plant Apocynum Venetum. The company sells its Chinese medicinal products and western medicines through wholesale customers; and its 13 Ankang retail pharmacies operating under the Sunsimiao Pharmacies name, as well as 66 pharmacies operated by third parties. It sells its decoction pieces on the Anhui Bozhou Chinese medicine transaction market to medical materials companies and Chinese patent medicine factories. The company sells its Luobuma textile products online through third party e-commerce websites, as well as through distributors under the Tenethealth brand; and yew trees and agricultural products primarily through its sales personnel, and group and institutional sales. The company was formerly known as Beijing Tenet Jove Technological Development Co., Ltd. and changed its name to Shineco, Inc. in June 2005. Shineco, Inc. was incorporated in 1997 and is based in Beijing, China.
Latest CDXC
- ChromaDex Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025
- ChromaDex to Present at the 37th Annual Roth Conference
- SVP, General Counsel Lopez Carlos Luis bought $2,146 worth of shares (273 units at $7.86), increasing direct ownership by 14% to 2,251 units (SEC Form 4)
- ChromaDex Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
- SEC Form 10-K filed by ChromaDex Corporation
- SEC Form 4 filed by Chief Executive Officer Fried Robert N
- ChromaDex Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025
Latest SISI
- Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- SEC Form NT 10-K filed by Shineco Inc.
- Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines
- Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
- Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth
- Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network
- Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology
- Shineco, Inc. to Effect 50:1 Reverse Stock Split
- Shineco Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- SEC Form DEF 14C filed by Shineco Inc.